search
Back to results

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan
Hydrochlorothiazide
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. All patients must give a separate written informed consent for participation in the open-label follow-up.

    • Mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmHg measured by manual cuff sphygmomanometer
    • Mean seated systolic blood pressure ≥ 140 mmHg, measured my manual cuff
    • A 24-hour mean diastolic blood pressure, measured by ABPM (ambulatory blood pressure measurement), of ≥ 85 mmHg
    • Age 18 or older
    • Patient's written informed consent in accordance with GCP (Good Clinical Practice) and local legislation

Exclusion Criteria:

  • Patients with a clinically significant change in ECG from baseline that was reported as an adverse event during the preceding clinical trial
  • Patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
  • Patients who discontinued the preceding telmisartan clinical trial due to an adverse event
  • Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Telmisartan

    Arm Description

    Outcomes

    Primary Outcome Measures

    Achievement of goal blood pressure response defined by a mean sitting diastolic blood pressure <90 mmHg
    Need for addition of hydrochlorothiazide or subsequent change in antihypertensive therapy
    Time to addition of hydrochlorothiazide or any subsequent change in antihypertensive therapy
    Mean sitting diastolic blood pressure during each visit
    Mean sitting systolic blood pressure during each visit
    Number of patient with adverse events
    Changes from baseline in heart rate
    Number of patients with abnormal changes in 12-Lead ECG (electrocardiogram)
    Number of patients with abnormal changes in laboratory parameters
    Number of patients with abnormal findings in physical examination

    Secondary Outcome Measures

    Full Information

    First Posted
    June 26, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02177422
    Brief Title
    Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
    Official Title
    Open-Label Follow-up Trial on Efficacy and Safety of Chronic Administration of Telmisartan 80 mg (Micardis®) Tablets as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    June 1998 (undefined)
    Primary Completion Date
    November 1999 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    The primary objective of this trial was to assess the efficacy and safety of telmisartan 80 mg during open-label, long-term treatment. An additional objective was to assess the efficacy and safety of concomitant administration of telmisartan 80 mg and HCTZ (Hydrochlorothiazide) and/or any other therapies commonly used in the treatment of hypertension.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Enrollment
    489 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Telmisartan
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan
    Intervention Description
    telmisartan 80 mg once daily
    Intervention Type
    Drug
    Intervention Name(s)
    Hydrochlorothiazide
    Intervention Description
    12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure < 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
    Primary Outcome Measure Information:
    Title
    Achievement of goal blood pressure response defined by a mean sitting diastolic blood pressure <90 mmHg
    Time Frame
    Up to one year
    Title
    Need for addition of hydrochlorothiazide or subsequent change in antihypertensive therapy
    Time Frame
    Up to one year
    Title
    Time to addition of hydrochlorothiazide or any subsequent change in antihypertensive therapy
    Time Frame
    Up to one year
    Title
    Mean sitting diastolic blood pressure during each visit
    Time Frame
    At months 3, 6, 9, 12
    Title
    Mean sitting systolic blood pressure during each visit
    Time Frame
    At months 3, 6, 9, 12
    Title
    Number of patient with adverse events
    Time Frame
    Up to one year
    Title
    Changes from baseline in heart rate
    Time Frame
    Baseline and at months 3, 6, 9, 12
    Title
    Number of patients with abnormal changes in 12-Lead ECG (electrocardiogram)
    Time Frame
    Baseline and 12 months
    Title
    Number of patients with abnormal changes in laboratory parameters
    Time Frame
    Baseline and 12 months
    Title
    Number of patients with abnormal findings in physical examination
    Time Frame
    Baseline and at 12 month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. All patients must give a separate written informed consent for participation in the open-label follow-up. Mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmHg measured by manual cuff sphygmomanometer Mean seated systolic blood pressure ≥ 140 mmHg, measured my manual cuff A 24-hour mean diastolic blood pressure, measured by ABPM (ambulatory blood pressure measurement), of ≥ 85 mmHg Age 18 or older Patient's written informed consent in accordance with GCP (Good Clinical Practice) and local legislation Exclusion Criteria: Patients with a clinically significant change in ECG from baseline that was reported as an adverse event during the preceding clinical trial Patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan Patients who discontinued the preceding telmisartan clinical trial due to an adverse event Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.260_U00-1706.pdf
    Description
    Related Info

    Learn more about this trial

    Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension

    We'll reach out to this number within 24 hrs